JP2018508181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508181A5 JP2018508181A5 JP2017518379A JP2017518379A JP2018508181A5 JP 2018508181 A5 JP2018508181 A5 JP 2018508181A5 JP 2017518379 A JP2017518379 A JP 2017518379A JP 2017518379 A JP2017518379 A JP 2017518379A JP 2018508181 A5 JP2018508181 A5 JP 2018508181A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- cells
- gpc3
- peptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims description 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 81
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 52
- 102100032530 Glypican-3 Human genes 0.000 claims description 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 108010029172 HLA-DR9 antigen Proteins 0.000 claims description 34
- 108700037339 HLA-DR13 antigen Proteins 0.000 claims description 26
- 210000000447 Th1 cell Anatomy 0.000 claims description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 21
- 230000006698 induction Effects 0.000 claims description 17
- 108010064366 HLA-DPw2 antigen Proteins 0.000 claims description 16
- 108010086066 HLA-DR8 antigen Proteins 0.000 claims description 15
- 108010063970 HLA-DR15 antigen Proteins 0.000 claims description 14
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 14
- 108010055807 HLA-DR14 Proteins 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 9
- 108091054438 MHC class II family Proteins 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- -1 HLA-DR52b Proteins 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 102000043131 MHC class II family Human genes 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 12
- 238000000034 method Methods 0.000 claims 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 5
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 42
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 30
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 30
- 108010058597 HLA-DR Antigens Proteins 0.000 description 20
- 102000006354 HLA-DR Antigens Human genes 0.000 description 20
- 102100037850 Interferon gamma Human genes 0.000 description 19
- 108010074328 Interferon-gamma Proteins 0.000 description 19
- 230000004044 response Effects 0.000 description 18
- 230000001419 dependent effect Effects 0.000 description 15
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 9
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 9
- 230000036755 cellular response Effects 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 9
- 230000000735 allogeneic effect Effects 0.000 description 8
- 238000011510 Elispot assay Methods 0.000 description 7
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 7
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 102000048373 human GPC3 Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 description 3
- 108010001041 HLA-DR7 Antigen Proteins 0.000 description 3
- 108010061311 HLA-DRB3 Chains Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 description 2
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 2
- 108010045483 HLA-DPB1 antigen Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000599782 Homo sapiens Insulin-like growth factor 2 mRNA-binding protein 3 Proteins 0.000 description 1
- 101000702394 Homo sapiens Signal peptide peptidase-like 2A Proteins 0.000 description 1
- 101000960621 Homo sapiens U3 small nucleolar ribonucleoprotein protein IMP3 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102100030403 Signal peptide peptidase-like 2A Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014248759 | 2014-12-09 | ||
| JP2014248759 | 2014-12-09 | ||
| PCT/JP2015/006029 WO2016092787A1 (en) | 2014-12-09 | 2015-12-04 | Gpc3 epitope peptides for th1 cells and vaccines containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018508181A JP2018508181A (ja) | 2018-03-29 |
| JP2018508181A5 true JP2018508181A5 (enExample) | 2019-01-17 |
Family
ID=56107012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518379A Withdrawn JP2018508181A (ja) | 2014-12-09 | 2015-12-04 | Ｔｈ１細胞のためのＧＰＣ３エピトープペプチドおよびこれを含有するワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170362287A1 (enExample) |
| EP (1) | EP3230301A4 (enExample) |
| JP (1) | JP2018508181A (enExample) |
| TW (1) | TW201636358A (enExample) |
| WO (1) | WO2016092787A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018143454A1 (ja) * | 2017-02-06 | 2018-08-09 | 国立研究開発法人国立がん研究センター | 新規ｔ細胞受容体 |
| IL268919B2 (en) * | 2017-03-03 | 2023-10-01 | Treos Bio Zrt | A personalized immunogenic peptide identification platform |
| WO2025110187A1 (ja) * | 2023-11-21 | 2025-05-30 | 国立研究開発法人国立がん研究センター | Ｈｌａ－ａ０２拘束性グリピカン３由来ペプチド特異的ｔｃｒ |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001011033A2 (en) * | 1999-08-04 | 2001-02-15 | Abbott Laboratories | Identification of genes essential for the survival of haemophilus influenzae through genome scanning by transposition mutagenesis |
| AU2003254950A1 (en) * | 2002-08-26 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | Peptides and drugs containing the same |
| KR101304243B1 (ko) * | 2005-08-09 | 2013-09-05 | 온코세라피 사이언스 가부시키가이샤 | ＨＬＡ-Ａ2 양성 환자용 글리피칸-3(ｇｌｙｐｉｃａｎ-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약 |
| JP5025159B2 (ja) * | 2006-04-28 | 2012-09-12 | シスメックス株式会社 | 生体成分測定装置 |
| TW201425333A (zh) * | 2007-04-11 | 2014-07-01 | Oncotherapy Science Inc | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 |
| US8088574B2 (en) * | 2007-07-31 | 2012-01-03 | Wisconsin Alumni Research Foundation | Poly(A) polymerase |
| TW200932260A (en) * | 2007-11-28 | 2009-08-01 | Oncotherapy Science Inc | STAT3 epitope peptides |
| JP2013523084A (ja) * | 2010-04-09 | 2013-06-17 | オンコセラピー・サイエンス株式会社 | Ｃｄｃａ５ペプチドおよびそれを含むワクチン |
| US8928735B2 (en) * | 2011-06-14 | 2015-01-06 | Microsoft Corporation | Combined lighting, projection, and image capture without video feedback |
| US9091651B2 (en) * | 2011-12-21 | 2015-07-28 | Integrated Diagnostics, Inc. | Selected reaction monitoring assays |
| US20130217122A1 (en) * | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
| US9016790B2 (en) * | 2012-10-04 | 2015-04-28 | William E. Voyce, IV | Convertible seating reclining chair |
| TWI693073B (zh) * | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑 |
-
2015
- 2015-12-01 TW TW104140060A patent/TW201636358A/zh unknown
- 2015-12-04 WO PCT/JP2015/006029 patent/WO2016092787A1/en not_active Ceased
- 2015-12-04 EP EP15867784.9A patent/EP3230301A4/en not_active Withdrawn
- 2015-12-04 US US15/534,311 patent/US20170362287A1/en not_active Abandoned
- 2015-12-04 JP JP2017518379A patent/JP2018508181A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7535489B2 (ja) | 治療用抗癌ネオエピトープワクチン | |
| JP6931598B2 (ja) | Ｃｄ４＋ｔ細胞応答を向上するための修飾されたエピトープ | |
| Casares et al. | Immunization with a tumor‐associated CTL epitope plus a tumor‐related or unrelated Th1 helper peptide elicits protective CTL immunity | |
| AU2009214039B2 (en) | Immunogenic control of tumours and tumour cells | |
| WO2021236854A1 (en) | Sars-cov-2 vaccines | |
| Meng et al. | Fine specificity analysis of an HLA-A2. 1-restricted immunodominant T cell epitope derived from human α-fetoprotein | |
| JP6780852B2 (ja) | Ｂ型肝炎ウイルス感染に対する治療ワクチン接種のための合成長鎖ペプチド（ｓｌｐ） | |
| TW514530B (en) | Tumor vaccines and methods for their production | |
| KR20210093933A (ko) | 개선된 산화환원 효소 모티프를 갖는 면역원성 펩티드 | |
| Chan et al. | The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA | |
| JP2025066801A (ja) | ペプチド | |
| CN115942942A (zh) | 感染性疾病抗原和疫苗 | |
| CN103596971B (zh) | 通过删除由nkt细胞识别的表位来调整抗原免疫原性 | |
| JP2018508181A5 (enExample) | ||
| CN112867502A (zh) | Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗 | |
| WO2021224397A1 (en) | Immunogenic peptides with extended oxidoreductase motifs | |
| DK3069138T3 (en) | CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF | |
| Swiniarski et al. | Immune response enhancement by in vivo administration of B7. 2Ig, a soluble costimulatory protein | |
| HK40034610A (en) | Modified epitopes for boosting cd4+ t-cell responses | |
| AU2013270496B2 (en) | Immunogenic control of tumours and tumour cells | |
| Li | Role of heat shock protein in chaperoning tumor antigens and modulating anti-tumor immunity | |
| Moran | Characterization of dendritic cells transduced with Venezuelan equine encephalitis virus replicon particles as therapeutic cancer vaccines | |
| AU2016202443A1 (en) | Immunogenic control of tumours and tumour cells | |
| CN107353339A (zh) | Gas7肿瘤抗原及其应用 |